Gelucire44/14 as a novel absorption enhancer for drugs with different hydrophilicities: In vitro and in vivo improvement on transcorneal permeation

Journal of Pharmaceutical Sciences

Volumn 100, Issue 8, 2011, Pages 3186-3195

  Liu, Rui ^a,b   Liu, Zhidong ^a,b   Zhang, Chengui ^c   Zhang, Boli ^b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c Engineering Center of Tianjin Zhongxin Pharmaceutical Group Corporation Ltd   (China)

Author keywords

Absorption enhancer; Gelucire44 14; Microdialysis; Ocular bioavailability; Ocular irritation; Ophthalmic drug delivery; Permeability; Pharmacokinetics; Surfactant; Transcorneal permeation

Indexed keywords

BAICALIN; BERBERINE; CURCUMIN; DRUG VEHICLE; GELUCIRE; GELUCIRE44 14; MANGIFERIN; PUERARIN; RIBAVIRIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CONCENTRATION RESPONSE; CORNEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG PENETRATION; HYDROPHILICITY; NONHUMAN; RABBIT;

EID: 79958801138     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22540     Document Type: Article

References (38)

1. Kaur IP, Smitha R. 2002. Penetration enhancers and ocular bioadhesives: Two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm 28:353-369.
2. Saettone MF, Chetoni P, Cerbai R, Mazzanti G, Braghiroli L. 1996. Evaluation of ocular permeation enhancers: In vitro effects on corneal transport of four β-blockers, and in vitro/in vivo toxic activity. Int J Pharm 142:103-113.
3. Hornof MD, Bernkop-Schürch A. 2002. In vitro evaluation of the permeation enhancing effect of polycarbophil-cysteine conjugates on the cornea of rabbits. J Pharm Sci 91:2588-2592.
4. Kikuchi T, Suzuki M, Kusai A, Iseki K, Sasaki H. 2005. Synergistic effect of EDTA and boric acid on corneal penetration of CS-088. Int J Pharm 290:83-89.
5. Liu ZD, Li JW, Nie SF, Guo H, Pan WS. 2006. Effects of Transcutol P on the corneal permeability of drugs and evaluation of its ocular irritation of rabbit eyes. J Pharm Pharmacol 58:1-6.
6. Nemoto E, Ueda H, Akimoto M, Natsume H, Morimoto Y. 2007. Ability of poly-l-arginine to enhance drug absorption into aqueous humor and vitreous body after instillation in rabbits. Biol Pharm Bull 30:1768-1772.
7. Afouna MI, Khedr A, Abdel-Naim AB, Al-Marzoqi A. 2010. Influence of various concentrations of terpene-4-ol enhancer and carbopol-934 mucoadhesive upon the in vitro ocular transport and the in vivo intraocular pressure lowering effects of dorzolamide ophthalmic formulations using albino rabbits. J Pharm Sci 99:119-127.
8. Di Colo G, Burgalassi S, Zambito Y, Monti D, Chetoni P. 2004. Effects of different N-trimethyl chitosans on in vitro/in vivo ofloxiacin transcorneal permeation. J Pharm Sci 93:2851-2862.
9. Roussin P, Laforêt JP. 1997. Gelucire®44/14: A high-performance system to enhance bioavailability of poorly water soluble drugs. Bull Tech Gattefossé 90:51-57.
10. Roussin P, Laforêt JP. 1997. Investigating semi-solid formulations: Physical characterization and stability study of Gelucire registered trade mark 44/14. Fram Vestn 48:260-261.
11. Sinha S, Ali M, Baboota S, Ahuja A, Kumar A, Ali J. 2010. Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir. AAPS PharmSciTech 11:518-527.
12. Lukovac S, Gooijert KE, Gregory PC, Shlieout G, Stellaard F, Rings EH, Verkade HJ. 2010. Gelucire44/14® improves fat absorption in rats with impaired lipolysis. Biochim Biophys Acta 1801:665-673.
13. Koga K, Takarada N, Takada K. 2010. Nano-sized water-in-oil-in-water emulsion enhances intestinal absorption of calcein, a high solubility and low permeability compound. Eur J Pharm Biopharm 74:223-232.
14. Tran TT, Tran PH, Lee BJ. 2009. Dissolution-modulating mechanism of alkalizers and polymers in a nanoemulsifying solid dispersion containing ionizable and poorly water-soluble drug. Eur J Pharm Biopharm 72:83-90.
15. Mehuys E, Remon JP, Korst A, Van Bortel L, Mols R, Augustijns P. 2005. Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire core. J Control Release 107:523-536.
16. Barker SA, Yap SP, Yuen KH, McCoy CP, Murphy JR, Craig DQ. 2003. An investigation into the structure and bioavailability of α-tocopherol dispersions in Gelucire 44/14. J Control Release 91:477-488.
17. Li X, Nie SF, Kong J, Li N, Ju CY, Pan WS. 2008. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm 363:177-182.
18. Moreira TS, Sousa VP, Pierre MB. 2010. A novel transdermal delivery system for the anti-inflammatory lumiracoxib: Influence of oleic acid on in vitro percutaneous absorption and in vivo potential cutaneous irritation. AAPS PharmSciTech 11:621-629.
19. Patel K, Trivedi S, Luo S, Zhu X, Pal D, Kern ER, Mitra AK. 2005. Synthesis, physicochemical properties and antiviral activities of ester prodrugs of ganciclovir. Int J Pharm 305:75-89.
20. Camber O. 1985. An in vitro model for determination of drug permeability through the cornea. Acta Pharm Suec 22:335-342.
21. Schoenwald RD, Huang HS. 1983. Corneal penetration behavior of β- blocking agents: Physicochenmical factors. J Pharm Sci 72:1266-1272.
22. Monti D, Chetoni P, Burgalassi S, Najarro M, Saettone MF. 2002. Increased corneal hydration induced by potential ocular penetration enhancers: Assessment by differential scanning calorimetry (DSC) and by desiccation. Int J Pharm 232:139-147.
23. Lallemand F, Furrer P, Felt-Baeyens O, Gex-Fabry M, Dumont JM, Besseghir K, Gurny R. 2005. A novel water-soluble cyclosporine A prodrug: Ocular tolerance and in vivo kinetics. Int J Pharm 295:7-14.
24. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. 2002. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 238:241-245.
25. Rittenhouse KD, Pollack GM. 2000. Microdialysis and drug delivery to the eye. Adv Drug Deliv Rev 45:229-241.
26. Burngay PM, Morrison PF, Dedrick RL. 1990. Steady-state theory for quantitative microdialysis of solutes and water in vivo and in vitro. Life Sci 46:105-119.
27. Liu ZD, Zhang XH, Li JW, Liu R, Shu LX, Jin J. 2009. Effects of Labrasol on the corneal delivery of baicalin. Drug Deliv 16:399-304.
28. Katragadda S, Gunda S, Hariharan S, Mitra AK. 2008. Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: Evaluation of their utility in treating ocular HSV infections. Int J Pharm 359:15-24.
29. Jarvinen K, Jarvinen T, Urtti A. 1995. Ocular absorption following topical delivery. Adv Drug Dev Rev 16:3-19.
30. Hochman J, Artursson P. 1994. Mechanism of absorption enhancement and tight junction regulation. J Control Release 29:253-267.
31. Urbán-Morlán Z, Ganem-Rondero A, Melgoza-Contreras LM, Escobar-Chávez JJ, Nava-Arzaluz MG, Quintanar-Guerrero D. 2010. Preparation and characterization of solid lipid nanoparticles containing cyclosporine by the emulsification-diffusion method. Int J Nanomed 5:611-620.
32. Ren S, Park MJ, Sah H, Lee BJ. 2008. Effect of pharmaceutical excipients on aqueous stability of rabeprazole sodium. Int J Pharm 350:197-204.
33. Shimpi SL, Chauhan B, Mahadik KR, Paradkar A. 2005. Stabilization and improved in vivo performance of amorphous etoricoxib using Gelucire50/13. Pharm Res 22:1727-1734.
34. Jiao J. 2008. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv Drug Deliv Rev 60:1663-1673.
35. Roggeband R, York M, Pericoi M, Braun W. 2000. Eye irritation responses in rabbit and man after single applications of equal volumes of undiluted model liquid detergent products. Food Chem Toxicol 38:727-734.
36. Anand BS, Katragadda S, Gunda S, Mitra AK. 2006. In vivo ocular pharmacokinetics of acyclovir dipepetide ester prodrugs by microdialysis in rabbits. Mol Pharm 3:431-440.
37. Aggarwal D, Pal D, Mitra AK, Kaur IP. 2007. Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. Int J Pharm 338:21-26.
38. Mori S, Matsuura A, Rama Prasad YV, Takada K. 2004. Studies on the intestinal absorption of low molecular weight heparin using saturated fatty acids and their derivatives as an absorption enhancer in rats. Biol Pharm Bull 27:418-421.